SVNS.LSE Solvonis Therapeutics plc

Healthcare Biotechnology London Exchange
0.0009 GBX
Close of Oct 31, 2026
0.0900 0.3340
Market cap
GBX 6.47M
P/E
-
P/B
1.56x
ROE
-119.5%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.

Is SVNS.LSE undervalued?

Graham number

The Graham number of Solvonis Therapeutics plc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Solvonis Therapeutics plc fundamental analysis

No fundamental analysis for Solvonis Therapeutics plc yet.

Solvonis Therapeutics plc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Solvonis Therapeutics plc

Solvonis Therapeutics plc, a clinical-stage biopharmaceutical company, develops medicines for addiction, psychiatry, and neurology disorders. The company develops SVN-001, an NMDA receptor antagonist that is in Phase III clinical trial for the treatment of severe alcohol use disorder; and SVN-002, which has completed Phase I clinical trial to treat moderate to severe alcohol use disorder. Its pre-clinical stage product consists of SVN-114 for the treatment of post-traumatic …

Full company profile